Overweight children are more vulnerable to early-onset hypertension. Childhood obesity is driving a rise in high blood ...

Hypertension, commonly known as high blood pressure, is a major risk factor for cardiovascular diseases. It affects millions ...

A 65-year-old woman presents to her primary care provider with a chief complaint of "feeling winded" for the last 3 weeks.

SGLT2 inhibitor use is associated with a reduced risk of hyperkalemia and lower rates of renin-angiotensin-aldosterone system ...

Hypertension is a major global health challenge, affecting millions and serving as a key risk factor for cardiovascular and renal diseases. While endocrine ...

SGLT2 Inhibitors Linked to Lower Hyperkalemia Risk and Improved RAASi Continuation suggests a new study published in the JAMA ...

High blood pressure frequently occurs in people with diabetes. Learn about the relationship, risks, and treatments for ...

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

Meanwhile, Novo Nordisk struck deals with several telehealth companies to sell its GLP-1 drug semaglutide for obesity directly to patients. (STAT) Sequel Med Tech announced plans to integrate its ...

Hypertension commonly co-exists with obstructive sleep apnea (OSA). However, the role of renin-angiotensin-aldosterone system (RAAS) in the development of hypertension in OSA patients remains poorly ...

“Aldosterone synthase inhibition may address the aldosterone breakthrough that occurs with long-term use of angiotensin-converting–enzyme inhibitors or angiotensin-receptor blockers and is a risk ...